title: A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
abstract: Belotecan (Camtobell, CKD602) is a new camptothecin derivative antitumor agent that belongs to the topoisomerase inhibitors. The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan as a second-line therapy in patients with small cell lung cancer (SCLC). Patients who were previously treated for SCLC were entered into the study. Belotecan was given by daily intravenous infusion for five consecutive days, every three weeks. Twenty-five patients were enrolled in this study. On an intention-to-treat basis, belotecan induced an overall response rate of 24%, a median overall survival of 9.9 months, a median time to progression of 2.2 months, and a 1-year survival rate of 38.3%. Grade 3/4 neutropenia developed in 88.0% of patients and grade 3/4 thrombocytopenia in 40.0%. Nonhematologic toxicity of grade 3 or 4 was low. The results suggest that belotecan is relatively active and well tolerated as a second-line agent in patients with SCLC.
authors.affiliation: Division of Pulmonology, Department of Internal Medicine, St Mary's Hospital, The Catholic University of Korea, Republic of Korea.
authors.forename: Chin Kook
authors.initials: CK
authors.lastname: Rhee
authors.forename: Sang Haak
authors.initials: SH
authors.lastname: Lee
authors.forename: Ju Sang
authors.initials: JS
authors.lastname: Kim
authors.forename: Seung Joon
authors.initials: SJ
authors.lastname: Kim
authors.forename: Seok Chan
authors.initials: SC
authors.lastname: Kim
authors.forename: Young Kyoon
authors.initials: YK
authors.lastname: Kim
authors.forename: Hyun Hee
authors.initials: HH
authors.lastname: Kang
authors.forename: Hyoung Kyu
authors.initials: HK
authors.lastname: Yoon
authors.forename: Jeong Sup
authors.initials: JS
authors.lastname: Song
authors.forename: Hwa Sik
authors.initials: HS
authors.lastname: Moon
authors.forename: Jin Woo
authors.initials: JW
authors.lastname: Kim
authors.forename: Chi Hong
authors.initials: CH
authors.lastname: Kim
authors.forename: Byoung Yong
authors.initials: BY
authors.lastname: Shim
authors.forename: Hoon Kyo
authors.initials: HK
authors.lastname: Kim
authors.forename: Der Sheng
authors.initials: DS
authors.lastname: Sun
authors.forename: Kwan Hyoung
authors.initials: KH
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*; D016019:Survival Analysis; D059004:Topoisomerase I Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D002166:Camptothecin